Enhanced AAV-mediated gene transfer for retinal therapies
US10266845B2 · kind B2 · utility
3Cited by
2References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 24, 2016 |
| Grant date | Apr 23, 2019 |
| Priority date | — |
| Expiry date | Sep 12, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2830/008
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein are capsid proteins and adeno-associated viruses capable of targeting various types of ocular cells including bipolar and horizontal cells. Also described herein are methods of treating various ocular disorders in a subject in need thereof by administering to the subject an effective concentration of a composition comprising the recombinant adeno-associated virus (AAV) of the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.